港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

高瓴概念

466.075

-1.678-0.36%

漲家數：20

跌家數：32

平家數：3

市盈率：- -

高：474.196

開：467.729

低：464.409

收：467.752

資料載入中...

總覽新聞資訊

上海鴻達山供應鏈管理有限公司註冊“葉盛全”商標獲核准

浙商重點推薦||特步國際·馬莉/史凡可/詹陸雨

浙商证券研究所

昂利康(002940.SZ)：創新藥注射用ALK-N001獲得藥物臨牀試驗批准通知書

【首藥控股：擬不超7.87億元建設新藥研發與產業化基地項目】首藥控股4月27日晚間公告，公司擬以自有及自籌資金不超過7.87億元，在亦莊新城國際醫藥創新公園自主建設新的“首藥控股新藥研發與產業化基地”項目，並與北京經濟技術開發區管委會簽署《經濟發展合作協議》。該合作協議生效後，公司將按照招拍掛供應程序取得項目宗地，建設包括研發中心、質控中心、臨牀試驗中心、銷售中心及生產基地在內的公司新總部，建設期3年。

翰森製藥(03692.HK)恆美達獲國家藥監局簽發藥品註冊證

阿斯达克财经

【四環醫藥(00460.HK)：渼顏空間自主研發的聚乳酸面部填充劑(童顏針)獲得國家藥監局上市批准】四環醫藥(00460.HK)發佈公告，集團旗下渼顏空間生物科技(吉林)有限公司自主研發的聚乳酸面部填充劑(該產品)正式獲得中國國家藥品監督管理局批准的第三類醫療器械註冊證，用以糾正中重度鼻唇溝皺紋。標誌着四環醫藥在再生醫美領域的又一重大突破，進一步鞏固了集團在高端醫美材料市場的技術領先地位。

信達生物(01801.HK)第三代肺癌靶向藥物奧壹新獲准上市

阿斯达克财经

君實生物(01877.HK)特瑞普利單抗新適應症上市申請獲批

阿斯达克财经

石藥集團(01093.HK)新藥SYH2068注射液獲准開展臨牀試驗

阿斯达克财经

海底撈“折騰”背後：藏着餐飲行業哪些新機遇

成都智叩醫療器械科技有限公司註冊“鑫郎中”商標獲核准

君實生物，2025沒有退路

長春金賽藥業有限責任公司藥品申請臨牀試驗默示許可獲受理

江蘇威凱爾醫藥科技股份有限公司藥品申請臨牀試驗默示許可獲受理

山東京衞製藥有限公司藥品申請臨牀試驗默示許可獲受理

安徽中盛溯源生物科技有限公司藥品申請臨牀試驗默示許可獲受理

和徑醫藥科技（上海）有限公司藥品申請臨牀試驗默示許可獲受理

四川美大康佳樂藥業有限公司藥品申請臨牀試驗默示許可獲受理

士澤生物醫藥（上海）有限公司藥品申請臨牀試驗默示許可獲受理

港灣周評|劉強東發起外賣大戰，今年搶10%市場份額？

Ofweek维科网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1583/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":466.07452,"timestamp":1745568501401,"preClose":467.7521,"halted":0,"volume":592708408,"delay":0,"changeRate":-0.003586,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-1.677582,"latestTime":"04-25 16:00:00","open":467.72882,"high":474.19583,"low":464.4094,"amount":14876747483,"amplitude":0.020922,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745803800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745544600000,1745553600000],[1745557200000,1745568000000]],"pbRate":2.234092,"peRate":21.950815,"turnoverRate":0.00422,"increases":19,"decrements":31,"flats":3,"marketCap":2621670112960,"floatMarketCap":2056871367104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":474.19583,"amplitude":0.020922,"preClose":467.7521,"low":464.4094,"pbRate":"2.234092","latestPrice":466.07452,"volume":592708408,"delay":0,"open":467.72882,"prevYearClose":446.93042,"prevWeekClose":466.075,"prevMonthClose":505.776,"prevQuarterClose":505.776,"fiveDayClose":459.33,"twentyDayClose":493.662,"sixtyDayClose":445.14,"secType":"PLATE","market":"HK","turnoverRate":0.00422,"peRate":21.950815,"marketCap":2621670112960,"floatMarketCap":2056871367104,"timestamp":1745568501401,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":20,"down":32,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530666164","title":"上海鴻達山供應鏈管理有限公司註冊“葉盛全”商標獲核准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530666164","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530666164?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 04:45","pubTimestamp":1745786728,"startTime":"0","endTime":"0","summary":"天眼查财产线索显示，近日，上海鸿达山供应链管理有限公司申请注册“叶盛全”商标获核准，国际分类为43-餐饮住宿，商标注册号81672613。资料显示，上海鸿达山供应链管理有限公司法定代表人为朱葛文，成立于2012年，位于上海市，是一家以从事商务服务业为主的企业。企业注册资本50万人民币。通过天眼查大数据分析，上海鸿达山供应链管理有限公司共对外投资了1家企业，知识产权方面有商标信息1条。\n\n\r\n            责任编辑：钟离","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/28044549933123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1589","06862","BK1583","BK1591","LU2488822045.USD","BK1233","BK1604"],"gpt_icon":0},{"id":"2530684544","title":"浙商重點推薦||特步國際·馬莉/史凡可/詹陸雨","url":"https://stock-news.laohu8.com/highlight/detail?id=2530684544","media":"浙商证券研究所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530684544?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 22:25","pubTimestamp":1745763958,"startTime":"0","endTime":"0","summary":"“稳舵三帆”往期回顾《浙商重点推荐||小米集团-W·冯翠婷/徐紫薇》《浙商重大推荐||中际联合·邱世梁/张菁》《","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428031038a4697633&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428031038a4697633&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1512","BK1502","01368","BK1583","BK1168"],"gpt_icon":0},{"id":"2530453276","title":"昂利康(002940.SZ)：創新藥注射用ALK-N001獲得藥物臨牀試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453276","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453276?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 21:37","pubTimestamp":1745761057,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨昂利康公布，近日，浙江昂利康制药股份有限公司收到国家药品监督管理局签发的注射用ALK-N0011《药物临床试验批准通知书》。临床前研究结果显示，注射用ALK-N001在HT1080及CT26模型中，ALK-N001均能剂量依赖性抑制肿瘤生长。综合临床前研究结果，ALK-N001显示了良好的药效和安全性，是一款极具创新性与开发潜力的小分子偶联抗肿瘤药物，有望为晚期实体瘤患者提供新的治疗选择。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27213749931252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","BK4588","BK4585","BK1141","BK1583","BK1574","03347","06978","ALK","002940","BK4008","BK0239","BK1161","BK4500","159992"],"gpt_icon":0},{"id":"2530453653","title":"【首藥控股：擬不超7.87億元建設新藥研發與產業化基地項目】首藥控股4月27日晚間公告，公司擬以自有及自籌資金不超過7.87億元，在亦莊新城國際醫藥創新公園自主建設新的“首藥控股新藥研發與產業化基地”項目，並與北京經濟技術開發區管委會簽署《經濟發展合作協議》。該合作協議生效後，公司將按照招拍掛供應程序取得項目宗地，建設包括研發中心、質控中心、臨牀試驗中心、銷售中心及生產基地在內的公司新總部，建設期3年。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453653","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453653?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 21:24","pubTimestamp":1745760272,"startTime":"0","endTime":"0","summary":"首药控股4月27日晚间公告，公司拟以自有及自筹资金不超过7.87亿元，在亦庄新城国际医药创新公园自主建设新的“首药控股新药研发与产业化基地”项目，并与北京经济技术开发区管委会签署《经济发展合作协议》。该合作协议生效后，公司将按照招拍挂供应程序取得项目宗地，建设包括研发中心、质控中心、临床试验中心、销售中心及生产基地在内的公司新总部，建设期3年。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/27212449931207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1161","09939","BK1515","BK1583","BK1576","688197","BK1574","03347","159938","BK0239"],"gpt_icon":0},{"id":"2530432595","title":"翰森製藥(03692.HK)恆美達獲國家藥監局簽發藥品註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2530432595","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530432595?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 19:22","pubTimestamp":1745752920,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，恒美达(枸橼酸艾瑞芬净片)获中国国家药品监督管理局签发药品注册证书，用于成年和初潮后青少年女性的外阴阴道念珠菌病的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436149/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1191","03692","BK1589"],"gpt_icon":0},{"id":"2530243190","title":"【四環醫藥(00460.HK)：渼顏空間自主研發的聚乳酸面部填充劑(童顏針)獲得國家藥監局上市批准】四環醫藥(00460.HK)發佈公告，集團旗下渼顏空間生物科技(吉林)有限公司自主研發的聚乳酸面部填充劑(該產品)正式獲得中國國家藥品監督管理局批准的第三類醫療器械註冊證，用以糾正中重度鼻唇溝皺紋。標誌着四環醫藥在再生醫美領域的又一重大突破，進一步鞏固了集團在高端醫美材料市場的技術領先地位。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530243190","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530243190?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:57","pubTimestamp":1745751459,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK)发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂(该产品)正式获得中国国家药品监督管理局批准的第三类医疗器械注册证，用以纠正中重度鼻唇沟皱纹。标志着四环医药在再生医美领域的又一重大突破，进一步巩固了集团在高端医美材料市场的技术领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/27185749930234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1191","BK1593","159883","09996","BK1222","09997","000973.SH","BK1515","BK1574","159837","BK1600","00460","BK1100"],"gpt_icon":0},{"id":"2530436586","title":"信達生物(01801.HK)第三代肺癌靶向藥物奧壹新獲准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2530436586","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530436586?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:12","pubTimestamp":1745748720,"startTime":"0","endTime":"0","summary":"信达生物(01801.HK) 公布，第三代表皮生长因子受体“EGFR”酪氨酸激酶抑制剂（“TKI”）靶向药物奥壹新(利厄替尼片)新药上市申请获中国国家药品监督管理局批准，用于具有EGFR外显子19缺失或外显子21置换突变的局部晚期或复发转移性非小细胞肺癌成人患者的一线治疗。2024年10月，公司与江苏奥赛康就利厄替尼片在中国达成独家商业化合作。目前，奥壹新已在中国获批2项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436137/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","LU2488822045.USD","BK1583","LU1969619763.USD","BK1161","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2530433028","title":"君實生物(01877.HK)特瑞普利單抗新適應症上市申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2530433028","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530433028?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 17:49","pubTimestamp":1745747340,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布，特瑞普利单抗(商品名：拓益)用于不可切除或转移性黑色素瘤的一线治疗的新适应症上市申请获国家药品监督管理局批准。这是特瑞普利单抗在内地获批的第12项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132907304_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132907304_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436134/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01877","BK0239","BK1161","BK1583","BK1515","688180"],"gpt_icon":0},{"id":"2530330844","title":"石藥集團(01093.HK)新藥SYH2068注射液獲准開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530330844","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530330844?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 17:47","pubTimestamp":1745747220,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布，集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA)获中国国家药品监督管理局批准，可以在内地开展临床试验。该产品适用于治疗高脂蛋白血症，通过优化序列和化学修饰的策略来实现更持久的基因沉默效果，具有预防动脉粥样硬化性心血管疾病的潜力。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436132/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE0008369823.USD","IE0008368742.USD","IE00B5MMRT66.SGD","BK1515","LU1152091168.USD","LU1226288253.USD","IE00B031HY20.USD","LU1226287529.USD","01093","LU0067412154.USD","LU1152091754.HKD","03347","IE00B543WZ88.USD","LU1960683339.HKD","LU0501845795.SGD","LU0072913022.USD","BK1141","BK1521","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1583","IE00BZ08YT58.USD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU0326950275.SGD","BK1576","LU0880133367.SGD","LU1008478684.HKD","LU1226287875.USD","LU1807302812.USD","LU0140636845.USD","LU1226288170.HKD","LU1951186391.HKD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2530818124","title":"海底撈“折騰”背後：藏着餐飲行業哪些新機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2530818124","media":"联商网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530818124?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 14:56","pubTimestamp":1745736988,"startTime":"0","endTime":"0","summary":"都说头部品牌往往更能洞察行业新趋势，内卷竞争加剧下，几乎每个餐饮人都在思考如何做差异化，那么海底捞这些“个性化”动作背后，究竟藏着什么破局秘籍，又能给餐饮人带来哪些新机会和新思考呢？2024年，海底捞营业收入达到427.55亿元，同比上升3.1%；净利润47亿元，同比增长4.6%。具体到川味火锅代表海底捞来看，其人均消费从2023年首次下跌到百元以下达到99.1元后，2024年再次下探至97.5元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427151149a6ca1e1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427151149a6ca1e1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06862","BK1604","BK1589","BK1591","BK1233","LU2488822045.USD","BK1583"],"gpt_icon":0},{"id":"2530866674","title":"成都智叩醫療器械科技有限公司註冊“鑫郎中”商標獲核准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530866674","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530866674?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 14:01","pubTimestamp":1745733718,"startTime":"0","endTime":"0","summary":"天眼查财产线索显示，近日，成都智叩医疗器械科技有限公司申请注册“鑫郎中”商标获核准，国际分类为44-医疗园艺，商标注册号81560276。资料显示，成都智叩医疗器械科技有限公司法定代表人为朱维洪，成立于2019年，位于成都市，是一家以从事科技推广和应用服务业为主的企业。企业注册资本100万人民币。通过天眼查大数据分析，成都智叩医疗器械科技有限公司知识产权方面有商标信息44条，此外企业还拥有行政许可3个。\n\n\r\n            责任编辑：栎树","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27140149925723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1222","159883","BK1583","BK1100","BK1574","09996","09997"],"gpt_icon":0},{"id":"2530848317","title":"君實生物，2025沒有退路","url":"https://stock-news.laohu8.com/highlight/detail?id=2530848317","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530848317?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:27","pubTimestamp":1745731621,"startTime":"0","endTime":"0","summary":"康方生物的伊努西单抗、君实生物的昂戈瑞西单抗、恒瑞医药的瑞卡西单抗，这三款PCSK9药物应该都在紧张筹备2025国谈了。2025年医保谈判，将非常考验这三款产品的谈判技巧。2023年8月，信达的托莱西单抗上市，恰好赶上同期上市的诺华英克司兰钠降价相逼。信达只能死保2025年的医保资格，才能有实力和安进、赛诺菲一战。还好，托莱西单抗进医保后销量还不错，有机构预计2027年收入可达约5000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427132845a468ca6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427132845a468ca6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","BK1515","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2530848483","title":"長春金賽藥業有限責任公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530848483","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530848483?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，长春金赛药业有限责任公司联合申请药品“伏欣奇拜单抗注射液”，获得临床试验默示许可，受理号CXSL2500163。通过天眼查大数据分析，长春金赛药业有限责任公司共对外投资了17家企业，参与招投标项目743次，知识产权方面有商标信息507条，专利信息105条，此外企业还拥有行政许可85个。主要股东信息显示，长春金赛药业有限责任公司由长春高新技术产业（集团）股份有限公司持股99.5%、金磊持股0.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1141","BK1576","BK1583"],"gpt_icon":0},{"id":"2530835874","title":"江蘇威凱爾醫藥科技股份有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835874","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835874?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，江苏威凯尔医药科技股份有限公司联合申请药品“VC005片”，获得临床试验默示许可，受理号CXHL2500200。江苏威凯尔医药科技股份有限公司，成立于2010年，位于南京市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，江苏威凯尔医药科技股份有限公司共对外投资了3家企业，参与招投标项目19次，知识产权方面有商标信息12条，专利信息47条，此外企业还拥有行政许可74个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1161","09939","BK1515","BK1583","BK1576","BK1574","03347","159938"],"gpt_icon":0},{"id":"2530835584","title":"山東京衞製藥有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835584","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835584?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，山东京卫制药有限公司联合申请药品“米诺地尔泡沫剂（男用）”，获得临床试验默示许可，受理号CYHL2500041。山东京卫制药有限公司，成立于1993年，位于泰安市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，山东京卫制药有限公司共对外投资了2家企业，参与招投标项目1749次，知识产权方面有商标信息146条，专利信息129条，此外企业还拥有行政许可182个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK1141","01477","03347","BK1574","BK1583","BK1576"],"gpt_icon":0},{"id":"2530835324","title":"安徽中盛溯源生物科技有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835324","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835324?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，安徽中盛溯源生物科技有限公司、中盛溯源（广州）生物科技有限公司联合申请药品“NCR201注射液”，获得临床试验默示许可，受理号CXSL2500126。安徽中盛溯源生物科技有限公司，成立于2016年，位于合肥市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，安徽中盛溯源生物科技有限公司共对外投资了5家企业，参与招投标项目11次，知识产权方面有商标信息60条，专利信息30条，此外企业还拥有行政许可11个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","159837","BK1583","BK1576","03347"],"gpt_icon":0},{"id":"2530483315","title":"和徑醫藥科技（上海）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530483315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530483315?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，和径医药科技（上海）有限公司联合申请药品“HJ-002-03片”，获得临床试验默示许可，受理号CXHB2500069。和径医药科技（上海）有限公司，成立于2017年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，和径医药科技（上海）有限公司专利信息14条，此外企业还拥有行政许可3个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09939","BK1515","BK1141","BK1574","03347","BK1576","159938","BK1583","BK1161"],"gpt_icon":0},{"id":"2530365483","title":"四川美大康佳樂藥業有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530365483","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530365483?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，四川美大康佳乐药业有限公司联合申请药品“甘露醇山梨醇注射液”，获得临床试验默示许可，受理号CYHL2500033。通过天眼查大数据分析，四川美大康佳乐药业有限公司共对外投资了1家企业，参与招投标项目423次，知识产权方面有商标信息25条，专利信息22条，此外企业还拥有行政许可191个。主要股东信息显示，四川美大康佳乐药业有限公司由四川蓝剑投资管理有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1141","03347","BK1576"],"gpt_icon":0},{"id":"2530248331","title":"士澤生物醫藥（上海）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530248331","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530248331?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，士泽生物医药（上海）有限公司、士泽生物医药（苏州）有限公司联合申请药品“XS228细胞注射液”，获得临床试验默示许可，受理号CXSL2500121。士泽生物医药（上海）有限公司，成立于2021年，位于上海市，是一家以从事专业技术服务业为主的企业。主要股东信息显示，士泽生物医药（上海）有限公司由士泽生物医药（苏州）有限公司持股100%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","BK1141","03347","399441","161726","BK1583"],"gpt_icon":0},{"id":"2530102593","title":"港灣周評|劉強東發起外賣大戰，今年搶10%市場份額？","url":"https://stock-news.laohu8.com/highlight/detail?id=2530102593","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530102593?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 10:54","pubTimestamp":1745722463,"startTime":"0","endTime":"0","summary":"刘强东吹响的外卖大战将成为2025年或未来数年最明显的商战。公开信具体公布了对骑手的4项措施，以及向消费者致歉，自即日起，所有超时20分钟以上的外卖订单，京东全部免单。据京东消息，4月22日，京东外卖日单量已突破1000万单，覆盖166个城市。3月1日，京东外卖正式上线，当月24日日单量突破100万单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042710543994e450a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042710543994e450a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06618","LU0128522157.USD","IE0032431581.USD","09618","LU0029875118.USD","LU1366334651.USD","LU0051755006.USD","LU1282651121.HKD","IE00BGV7N243.SGD","LU0431992006.USD","LU1044874839.SGD","LU0048580855.USD","BK1571","LU0359201612.USD","BK1610","LU0320764599.SGD","JD","LU0359202008.SGD","LU0456842615.SGD","LU0259732245.USD","LU1328277881.USD","LU0868486357.SGD","BK1515","LU0588545490.SGD","LU0163747925.USD","LU0228367735.SGD","LU0314109678.HKD","LU0828237510.HKD","LU0315179316.USD","BK1583","LU1770034418.SGD","LU1720050803.USD","LU0370786039.SGD","LU1282651048.USD","LU1481107354.HKD","LU0456827905.SGD","LU1808992512.USD","BK1589","LU1251922891.USD","89618","LU0052750758.USD","LU0327786744.USD","LU0293314216.USD","BK1615","LU0348825331.USD","BK1588","LU1044876610.USD","86618","LU0469268626.HKD","LU0345775950.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":43,"pageCount":1,"totalSize":850,"code":"91000000","status":"200"}]}}